| Name | Title | Contact Details |
|---|
NEO U is a live streaming and on demand platform for trainers and brands to scale to a world-wide audience. We host top fitness experts and workout concepts from around the world in our state-of-the-art fitness hub in Midtown Manhattan.
Careage Hills is a Cherokee, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Patient Interaction is a Bronx, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded in 2012 by international bestselling authors, work-life balance experts, and holistic healthcare providers, Dr. Dave Braun and Dr. Troy Amdahl, Oola provides a simple and easy-to-follow lifestyle framework designed to lead you, step by step, to a life of less stress, more personal growth, and a clearer path toward living your unique purpose. The concept originally ideated in 1997 as Dr. Braun and Dr. Amdahl worked to better themselves in the seven key areas of life -- Fitness, Finance, Family, Field (career), Faith, Friends, and Fun. Since then, the Oola lifestyle has become a global phenomenon, with over a million followers in 40 countries actively creating their best lives. In 2021, Oola announced an affordable personal development eLearning platform to add to their offerings. Expected to launch in Summer 2021, the new platform will accelerate Oola`s goal of impacting one billion lives in seven years.
Cleveland BioLabs, Inc. (NASDAQ: CBLI) is an innovative bio pharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. Our proprietary platform of toll-like immune receptor activators has applications in radiation mitigation, oncology immunotherapy, and vaccines. We combine our proven scientific expertise and our depth of knowledge about our products’ mechanisms of action into a passion for developing drugs to save lives. Our proprietary drug candidates act via unique mechanisms that are designed to kill cancer and protect healthy cells. Our most advanced product candidate is entolimod, which we are developing as a radiation countermeasure and an immunotherapy for oncology and other indications. We have additional pipeline product candidates in various stages of development.